Leukemia Classification and Diagnosis
Introduction to Leukemia Subtypes
- The World Health Organization (WHO) classifies leukemia into four major categories: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML), with additional rare subtypes including acute leukemia of ambiguous lineage and mixed phenotype acute leukemia 1
Acute Myeloid Leukemia (AML)
- AML is defined by ≥20% myeloid blasts in peripheral blood or bone marrow, encompassing cells of granulocytic, monocyte/macrophage, erythroid, megakaryocytic, and mast cell lineages 1
- Key AML subtypes based on genetic and molecular features include Acute Promyelocytic Leukemia (APL), Core Binding Factor AML (CBF-AML), AML with normal karyotype, and AML with complex karyotype or monosomies 1
- Myeloid leukemia associated with Down syndrome is recognized as a distinct entity by the WHO classification, separate from other AML types due to unique clinical, biological, and genetic features 2
Acute Lymphoblastic Leukemia (ALL)
- ALL is divided into B-lymphoblastic leukemia/lymphoma and T-lymphoblastic leukemia/lymphoma based on lineage commitment 1
- Diagnostic criteria include ≥25% bone marrow lymphoblasts, though the presence of known recurring cytogenetic abnormalities associated with ALL can lead to diagnosis even with <20% bone marrow blasts 1
- Burkitt lymphoma/leukemia is NOT classified as B-ALL, as it represents a mature B-cell neoplasm 1
Rare and Ambiguous Leukemia Types
- Acute Leukemia of Ambiguous Lineage (ALAL) encompasses leukemias that either fail to show evidence of lineage commitment or demonstrate commitment to multiple lineages 1
- Mixed Phenotype Acute Leukemia (MPAL) accounts for 2-5% of all acute leukemias and is characterized by blast cells expressing lineage-defining markers of more than one hematopoietic lineage 1, 3
MDS/Myeloproliferative Neoplasms (MDS/MPN)
- This category includes chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML) BCR-ABL1 negative, and juvenile myelomonocytic leukemia (JMML) as disorders having overlapping dysplastic and proliferative features, according to the National Comprehensive Cancer Network (NCCN) 4
- CMML has been subdivided into proliferative-type (WBC count ≥13 x 10⁹/L) and dysplastic-type (WBC count <13 x 10⁹/L) 4
- JMML is a rare childhood cancer presenting in infants and young children with peripheral blood monocyte count ≥1 x 10⁹/L, blast percentage <20%, and absence of BCR/ABL1 rearrangement 4
Clinical Considerations
- A critical pitfall is failing to recognize APL immediately, as it requires immediate ATRA therapy upon clinical suspicion even before genetic confirmation due to high mortality risk 1
- The WHO classification system incorporates cytogenetic data, molecular genetics, immunophenotype, and clinical information to define clinically significant disease entities, making comprehensive diagnostic workup essential 1
- Risk stratification in AML is governed by karyotype and molecular features, with age, initial leukocyte counts, and whether the leukemia is de novo or secondary serving as critical prognostic factors 1